Recently, in a prospective multicenter phase II clinical trial, the salvage regimen of Venetoclax, AZA, and Homoharringtonine (VAH) in 96 patients with relapsed/refractory AML (43 post HSCT) granted high response rates (ORR 78.1% and CR 70.8%) and prolonged survival (median OS 22.1 months) with an acceptable safety profile, paving the way to further combinational therapies of Venetoclax with MCL1 inhibitors [65,79]. Here, MCL1 is linked to acute myeloid leukemia.